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Abstract
Pulmonary hypertension (PH) is a common comorbidity of sickle cell disease (SCD) with an
associated increased mortality risk, but its etiology is not well-understood. To evaluate the
hemodynamic characteristics, clinical predictors, and cardiovascular manifestations of elevated
pulmonary arterial pressure in this population, we performed noninvasive hemodynamic
assessments of 135 patients with SCD using Doppler echocardiography. A diagnosis of PH was
based on gender-, age-, and body mass index (BMI)-specific normal reference ranges for tricuspid
regurgitation jet velocities (TRV). A high TRV was noted in 34 (25%) of patients. Pulmonary
vascular resistance (PVR) was elevated in only 2 of the 34 patients (6%) with suspected PH, but
was significantly higher than in those with a normal TRV. In univariate regression, TRV
correlated with age, BMI, left atrial pressure, and right ventricular stroke volume, and was
negatively associated with hemoglobin and glomerular filtration rate. Left atrial pressure, right
ventricular stroke volume, and hemoglobin remained independent predictors of TRV in a
multivariate model. A higher TRV was also associated with larger right ventricular and right atrial
chamber sizes and higher N-terminal pro-brain natriuretic peptide levels. Our results suggest that
the mild elevation in TRV often observed in patients with SCD is rarely associated with a high
PVR, and that multiple factors – including the compensatory high output state associated with
anemia, pulmonary venous hypertension, and a pulmonary vasculopathy – may contribute to an
elevated pulmonary arterial pressure in these patients.
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Introduction
Pulmonary hypertension (PH), diagnosed noninvasively by an elevation in the tricuspid
regurgitation jet velocity (TRV), is a common comorbidity of sickle cell disease (SCD) with
an associated increased mortality risk 1–4. To gain insight into the hemodynamic
characteristics, clinical predictors, and cardiac manifestations of PH in adult patients with
SCD, we examined echocardiographic data from a registry of patients followed in the
University of North Carolina Sickle Cell Clinic. The objectives of this study were a) to
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noninvasively determine the prevalence of elevated pulmonary vascular resistance (PVR) in
SCD patients with suspected PH, b) to compare the predictors of TRV to those found to be
significant in the general population, and c) to assess the relationships between TRV and
right ventricular and right atrial remodeling and function.
Methods
The 135 study subjects represent a cohort of clinically stable patients with SCD followed in
the Sickle Cell Clinic at University of North Carolina Hospitals between 2004 and 2010.
Each clinic patient was offered enrollment, with the exclusion of those with evidence of
heart failure, acute painful episodes or episodes of acute chest syndrome within 4 weeks.
Enrolled subjects were not required to have symptoms attributable to PH, allowing
prospective screenings without referral bias. The study was approved by the institutional
review board at the University of North Carolina, and written informed consent was
obtained from all participants.
Demographic and clinical characteristics of the study subjects were determined by interview
and review of the medical record. Height, weight, blood pressure, and laboratory studies
were measured on a single clinic visit. Body mass index (BMI) was calculated as weight/
height2, in units of kg/m2. Seated blood pressure was measured with an automated device
(Dinamap) following a minimum of 10 minutes of rest, and pulse pressure was calculated as
the difference between systolic and diastolic pressures. Blood specimens were acquired for
creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-proBNP), and lactic
dehydrogenase; glomerular filtration rate was estimated using the abbreviated Modification
of Diet in Renal Disease formula.5
Echocardiograms were performed by 1 sonographer, using a protocol that included at least 3
cardiac cycles for each image. All studies were acquired with a Philips Sonos 5500 imaging
platform, and were stored in a digital format for subsequent analysis. In 2006, Tissue
Doppler Imaging was added to the protocol following a software upgrade.
All echocardiographic measurements were made in triplicate and averaged from
representative beats, using offline echo analysis software. To minimize temporal drift in
measurement tendencies, all measurements were batched and quantified at the study close
by 1 analyst who was blinded to the clinical characteristics of the study subjects.
Measurements of TR jet velocities were made separately by a single experienced
cardiologist. The following echocardiographic parameters were measured: 1) TRV was
measured by continuous wave Doppler signals acquired from the parasternal short axis, right
ventricular inflow, and apical 4-chamber views. Only waveforms with well-defined
“envelopes” were measured. Pulmonary arterial systolic pressure was estimated using the
modified Bernoulli equation and an assumed right atrial pressure of 10 mmHg (pulmonary
arterial systolic pressure = 4 × TRV2 + 10).62) The velocity-time integral of systolic flow
through the right ventricular outflow tract, a surrogate for right ventricular stroke volume7,
was measured by pulsed wave Doppler with the sample volume positioned to obtain the
“closing click” of the pulmonic valve. 3) PVR was estimated using the noninvasive PVR
index developed by Abbas, et al8: PVR index = 10 × (TRV/right ventricular outflow tract
time-velocity integral). An index > 1.75 was considered evidence of an elevated PVR. 4)
Left and right ventricular areas were measured by planimetry from the apical 4-chamber
view at end-diastole, tracing the endocardial borders and carefully avoiding papillary
muscles and trabeculae. The right atrial area was traced by planimetry at mid-systole. 5) The
ratio of mitral inflow to mitral annular early diastolic velocities (E/e′) was calculated as an
index of left atrial pressure9. The E-wave peak velocity was measured by pulsed wave
Doppler of the transmitral diastolic flow, with the sample volume placed at the mitral leaflet
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tips. The e′ peak velocity was measured by Tissue Doppler Imaging with the sample volume
placed in the lateral mitral annulus. 6) The tricuspid annulus s′ velocity, an indicator of right
ventricular function10, was obtained by placing the Tissue Doppler sample volume in the
lateral tricuspid annulus and measuring the peak systolic velocity.
Since the expected upper limits of pulmonary arterial systolic pressure are influenced by age
and obesity, we based the diagnosis of PH on gender-, age-, and BMI-specific normal
reference ranges derived from a large clinical database of echocardiographically normal
subjects6. A patient was classified as having “Suspected PH” if the TRV resulted in a
calculated pulmonary arterial systolic pressure that exceeded the 95% confidence interval
for both the gender- and age-specific reference range, and the gender- and BMI-specific
reference range. This approach minimizes the tendency to overestimate the prevalence of PH
due to marginally elevated TRV in overweight and older patients. Since TRV can usually be
quantified in patients with significantly elevated pulmonary arterial pressure11, we
categorized patients with unmeasureable TRV as having “No PH”.
All statistical analyses were performed using SAS 9.2, with significance at the α = .05 level
(2-sided). Mean values for PVR were calculated after dichotomizing PH, using the normal
gender-, age-, and BMI- specific reference ranges for calculated pulmonary arterial systolic
pressure. Significance of the stratified analysis was determined by Wilcoxon rank sums.
Linear correlations between TRV and echocardiographic, clinical, and laboratory variables
were tested with Spearman regression. Relationships between TRV and all 2-diminsional
echocardiographic measurements were tested by Spearman partial correlation, after
controlling for body surface area. Spearman partial correlation controlling for glomerular
filtration rate was used to test the relationship between NT-proBNP and TRV. Predictors of
TRV were modeled with stepwise linear regression, with gender, age, and BMI forced into
the model, and all parameter estimates standardized. Hemoglobin, lactate dehydrogenase,
glomerular filtration rate, smoking, the E/e′ ratio, pulse pressure, and the right ventricular
outflow tract velocity-time integral were entered into the model, along with interaction
terms. To meet assumptions of normality, TRV was log transformed.
Results
Characteristics of the study sample are summarized in Tables 1 and 2. Despite the relatively
young sample, significant chronic comorbidities were observed in some subjects. Eighteen
patients (13%) had Stage 3 or 4 chronic kidney disease (glomerular filtration rate 15–59 ml/
min/1.73m2). Nineteen subjects (14%) were hypertensive, based on a blood pressure
measurement > 140/90 mmHg in the clinic.
Tricuspid regurgitation could be detected and the velocity quantified in 104 (77%) of the
135 screening echocardiograms; none of the remaining patients had echocardiographic
findings (septal flattening or marked right ventricular enlargement and dysfunction)
suggestive of PH. Of the 104 patients with quantifiable TRV, 34 had a peak TRV suggesting
PH, using the gender-, age-, and BMI-specific reference ranges for calculated pulmonary
arterial systolic pressure. Thus, PH was suspected in 25% of patients. The distributions of
the TRV values in the patients with and without suspected PH are illustrated in Figure 1.
Ten subjects were classified as “No PH” despite a TRV ≥ 2.5 m/s, the partition value
sometimes used to define PH. Most patients with suspected PH had mild elevations in TRV;
20 (59%) had a TRV < 3.0 m/s. The average PVR index was significantly greater in patients
with suspected PH than in those without (1.4 ± 0.2 vs. 1.2 ± 0.2, p=.0001), but was still well
below the 1.75 cutoff for elevated PVR. Only 2 subjects with suspected PH (6%), with TRV
values of 3.0 and 3.9 m/s, respectively, had an elevated PVR index.
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Invasive measurements of pulmonary hemodynamics were examined in a convenience
sample of 12 subjects who had suspected PH (mean TRV = 3.1 m/s) and who underwent
right heart catheterization as part of their clinical evaluation within 3 years of the screening
echocardiogram. PH (defined as mean pulmonary arterial pressure ≥ 25 mmHg) was
confirmed in all but 1 of the 12 patients, and only a single patient had an elevated PVR
(defined as PVR > 3 Wood units).
Linear relationships between TRV and a priori selected variables are shown in Table 3.
TRV was correlated with age, BMI, E/e′ ratio, and right ventricular outflow tract velocity-
time integral, and negatively correlated with hemoglobin and glomerular filtration rate.
There was a trend toward a linear association between TRV and lactate dehydrogenase that
did not reach statistical significance. As shown in Table 4, left atrial pressure, right
ventricular stroke volume, and hemoglobin (at a borderline level of statistical significance)
were predictors of TRV in a multivariate regression model that explained 49% of the
variability. For every 1.0 unit increase in E/e′, the TRV increased by 12%. For every 1.0 g/
dL increase in hemoglobin, the TRV decreased by 13%. And, for every 1.0 cm increase in
the right ventricular outflow tract velocity-time integral, the TRV increased by 6%.
Relationships between TRV and indices of right heart structure and function and NT-
proBNP are shown in Table 5. Higher TRV was associated with larger right ventricular and
right atrial chamber sizes, more severe tricuspid regurgitation, and greater values of NT-
proBNP. TRV was not significantly correlated with tricuspid annulus s′ velocity. NT-
proBNP was related to right ventricular area (r = 0.18, p = 0.05) and right atrial area (r =
0.16, p = 0.08), as well as mitral E/e′ (r = 0.34, p = 0.0008) after adjusting for body surface
area and glomerular filtration rate; the relationships with right ventricular area (r = 0.22, p =
0.04) and right atrial area (r = 0.18, p = 0.09) remained similar after correcting for E/e′.
Discussion
Our data suggest that most adult patients with SCD and suspected PH, based on gender-,
age-, and BMI-specific reference values for TRV, have a normal PVR. A high TRV in SCD
patients is associated with older age, greater BMI, and an elevated left atrial pressure, as in
the general population12, but also with anemia and an elevated right ventricular stroke
volume. Although the elevation in TRV observed in patients with SCD is often mild, it is
nonetheless associated with remodeling of the right ventricle and right atrium and an
elevated NT-proBNP.
Our reported suspected PH prevalence of 25% is consistent with data from previous studies
that have based this diagnosis on an elevated TRV1–3, including a previous report from our
group that included many patients in the present cohort1. Whether PH can be confidently
diagnosed by Doppler echocardiography is controversial, however. Estimation of PASP
using the TRV gained widespread acceptance as a valuable method of screening for PH after
early publications demonstrating a close relationship between Doppler and invasive
measurements13, 14. Several subsequent studies have questioned the accuracy of this
technique7, 15. In a recent prospective, multicenter study in which patients with SCD and
suspected PH underwent right heart catheterization, only 24 of the 96 patients (25%) with a
TRV ≥2.5 m/s had a mean pulmonary arterial pressure ≥ 25 mmHg16.
The limited positive predictive value of an elevated TRV may be explained in part by
inaccuracies of the Doppler measurement and physiologic variations in pulmonary
hemodynamics. Many patients with SCD have TRV values that are marginally elevated, and
a small difference in the measurement can lead to a change in classification. Moreover, the
TRV estimates pulmonary arterial systolic pressure, while the invasive diagnosis of PH is
based on the mean pulmonary arterial pressure. The partition value of TRV used to define
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PH is also an important factor. Although a threshold TRV of ≥2.5 m/s is often used,
otherwise healthy individuals who are older or obese may have higher values6. Indeed, data
from a random sample of Olmsted County, Minnesota suggest that 25% of the general
population older than 45 years has a TRV ≥2.5 m/s12. We propose that basing the
noninvasive diagnosis of PH on gender-, age-, and BMI-specific reference values for TRV is
preferable to using a fixed velocity of 2.5 m/s in cohort studies of patients with SCD. This
strategy identifies a high-risk subset of patients with greater TRV than expected in the
general population, most of whom have PH on right heart catheterization.
The pathogenesis of PH in patients with SCD is complex. The compensatory high output
state resulting from chronic anemia may contribute to an elevated pulmonary arterial
pressure17–20. Pulmonary venous hypertension as a manifestation of left ventricular
dilatation and eccentric hypertrophy may be a significant factor in some patients21.
Hemolysis is also believed to play an important role, leading to nitric oxide depletion,
endothelin-1 release, and platelet activation, and ultimately resulting in a vasculopathy
characterized by endothelial dysfunction, increased vascular tone, inflammation,
hypercoagulability, and vascular remodeling21–24.
The relations between TRV and clinical and laboratory parameters observed in our cohort
are consistent with multiple pathogenic mechanisms contributing to PH in patients with
SCD. As in the general population, age and BMI are correlated with TRV. The strong,
independent associations of TRV with right ventricular outflow tract velocity-time integral,
a measure of right ventricular stroke volume, and the Doppler E/e′ ratio, an index of left
atrial pressure, support the importance of both high cardiac output and pulmonary venous
hypertension in the pathogenesis of PH in this population. A possible role for hemolysis is
suggested by the negative correlation of TRV with hemoglobin, and an association of
borderline statistical significance with lactate dehydrogenase.
To our knowledge, this is the first study to noninvasively examine the prevalence of elevated
PVR in adult SCD patients prospectively screened for PH by Doppler echocardiography. As
noted previously in pediatric populations17, 18, we found that a high TRV in our adult
patients with SCD was rarely associated with an elevated PVR. Similarly, Parent, et al16
found an elevated PVR on right heart catheterization in only a small proportion of patients
with high TRV. The normal values for PVR in our patients with suspected PH do not
necessarily imply an absence of pulmonary vascular disease; the PVR in these patients is
higher than in those with normal pulmonary arterial pressures, and may be inappropriately
high in association with a high cardiac output. Nonetheless, our findings suggest an
important – and perhaps predominant – role for the high output state associated with anemia
in the pathogenesis of PH in adult patients with SCD. While an elevated pulmonary arterial
pressure may be commonplace in SCD, pulmonary arterial hypertension -- defined by
consensus as an elevated pulmonary arterial pressure in association with a normal
pulmonary arterial wedge pressure and a PVR > 3 Wood units25 -- is found in a relatively
small minority of these patients.
Our study has some limitations that deserve acknowledgement. Our subjects were recruited
from a specialty clinic at a tertiary care medical center, and may not be representative of all
patients with SCD. As noted previously, echocardiography is not the “gold standard”
technique for assessing pulmonary arterial pressures or PVR, but is more feasible than right
heart catheterization for large-scale screenings. The noninvasive PVR index has not been
validated in SCD patients or in other populations characterized by a high cardiac output. As
with all cross-sectional studies, this analysis can demonstrate associations, but cannot prove
causation.
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Distributions of tricuspid regurgitation jet velocities, stratified by “Suspected Pulmonary
Hypertension” and “No Pulmonary Hypertension” classification.
Caughey et al. Page 8

























Caughey et al. Page 9
Table 1
Characteristics of the study population
Characteristic N Number (%) or Mean ± S.D.
Male 135 49 (36%)
Black 135 133 (99%)
Age (years) 135 39 ± 13
Smoker 135 43 (32%)
Body mass index (kg/m2) 135 26.6 ± 7.0
Creatinine (mg/dL) 135 1.0 ±0.7
Glomerular filtration rate (mL/min/1.73 m2) 135 124 ± 57
Hemoglobin (g/dL) 135 9.0 ± 1.8
Systolic blood pressure (mmHg) 135 124 ± 16
Diastolic blood pressure (mmHg) 135 71 ± 12
Pulse pressure (mmHg) 135 53 ± 13
N-terminal pro-brain natriuretic peptide (pg/mL) 131 392 ± 1254
Lactate dehydrogenase (U/L) 132 989 ± 480
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Table 2
Echocardiographic values for the study population
Characteristic N Mean ± S.D.
Tricuspid regurgitation velocity (m/s) 104 2.5 ± 0.4
Estimated pulmonary arterialsystolic pressure (mmHg) 104 36 ± 9
Right ventricular outflow tract velocity-time integral (cm) 134 20.1 ± 3.7
Pulmonary vascular resistance index 103 1.2 ± 0.2
E/e′ ratio 95 8.0 ± 3.7
Tricuspid annulus s′ (cm/s) 92 15.0 ± 2.5
Tricuspid regurgitation jet area (cm2) 126 4.9 ± 3.1
Right ventricular area (cm2) 130 23.4 ± 4.5
Right atrial area (cm2) 133 17.1 ± 3.9
Left ventricular area (cm2) 131 42.7 ± 6.4
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Table 3
Simple correlations of tricuspid regurgitation jet velocity with selected clinical and echocardiographic
variables
Variable N r p
Age, years 104 0.35 0.0003
Body mass index (kg/m2) 104 0.26 0.007
Hemoglobin (g/dL) 104 −0.22 0.02
Lactate dehydrogenase (U/L) 102 0.17 0.08
Glomerular filtration rate (mL/min/1.73 m2) 104 −0.47 <.0001
E/e′ ratio 76 0.60 <.0001
Right ventricular outflow tract velocity-time integral (cm) 103 0.39 <.0001
Pulse pressure (mmHg) 104 0.13 0.2
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Table 4
Results of multivariable regression model for predictors of tricsupid regurgitation jet velocity
Variable Standard Deviation Standardized Estimate p
Age (years) 13.8 0.145 0.1
Gender 0.5 0.114 0.2
Body mass index (kg/m2) 5.6 0.158 0.1
E/e′ ratio 4.1 0.484 < .0001
Hemoglobin (g/dL) 1.6 −0.204 0.06
Right ventricular outflow tract time-velocity integral (cm) 3.0 0.192 0.03
N = 76 R2 = 49%
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Table 5
Spearman correlations with tricuspid regurgitation jet velocity
Variable N r p
Right ventricular area (cm2)* 102 0.18 0.06
Right atrial area (cm2)* 103 0.27 0.007
Tricuspid annular s′ velocity (cm/s) 73 −0.18 0.1
Tricuspid regurgitant jet area (cm2) 98 0.25 0.01
N-terminal pro-brain natriuretic peptide (pg/mL)† 101 0.31 0.002
*
Controlling for body surface area
†
 Controlling for glomerular filtration rate
Am J Cardiol. Author manuscript; available in PMC 2013 May 01.
